Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies

BMC Endocrine Disorders

Volumn 14, Issue , 2014, Pages

  Sinclair, Alan ^a   Bode, Bruce ^b   Harris, Stewart ^c   Vijapurkar, Ujjwala ^d   Mayer, Cristiana ^d   Fung, Albert ^d   Shaw, Wayne ^d   Usiskin, Keith ^d   Desai, Mehul ^d   Meininger, Gary ^d  

^a LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^b ATLANTA DIABETES ASSOCIATES   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antihyperglycaemic agent; Canagliflozin; Older patients; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; LIPID; PLACEBO; GLUCOSIDE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; CLINICAL STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; VOLUME DEPLETION; ADOLESCENT; DIABETES MELLITUS, TYPE 2; META ANALYSIS (TOPIC); MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; YOUNG ADULT;

EID: 84899960517     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-14-37     Document Type: Article

References (25)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596. 10.1007/s00125-012-2534-0, 22526604.
2. Canadian Diabetes Association Clinical Practice Guidelines. [http://guidelines.diabetes.ca/], Canadian Diabetes Association.
3. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006, 368:29-36. 10.1016/S0140-6736(06)68967-8, 16815377.
4. International Diabetes Federation Global guidelines for type 2 diabetes. [http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf], International Diabetes Federation.
5. Meneilly GS, Knip A, Tessier D. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: diabetes in the elderly. Can J Diabetes 2013, 37(suppl):S184-S190.
6. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschope D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 2012, 11:122. 10.1186/1475-2840-11-122, 3508810, 23039216.
7. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012. 10.1056/NEJMsa1103053, 22111719.
8. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, for the Canagliflozin DIA 2001 Study Group Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012, 35:1232-1238. 10.2337/dc11-1926, 3357223, 22492586, for the Canagliflozin DIA 2001 Study Group.
9. Stenlöf K, Cefalu WT, Kim K-A, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382. 10.1111/dom.12054, 3593184, 23279307.
10. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013, 36:2508-2515. 10.2337/dc12-2491, 23564919.
11. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013, 41:72-84.
12. Cefalu WT, Leiter LA, Yoon K-H, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950. 10.1016/S0140-6736(13)60683-2, 23850055.
13. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473. 10.1111/dom.12090, 3654568, 23464594.
14. Lavalle-González F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013, 56:2582-2592. 10.1007/s00125-013-3039-1, 3825495, 24026211.
15. Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013, 67:1267-1282. 10.1111/ijcp.12322, 24118688.
16. Stenlöf K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, Tong C, Canovatchel W, Meininger G. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014, 30:163-175. 10.1185/03007995.2013.850066, 24073995.
17. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012, 14:539-545. 10.1111/j.1463-1326.2012.01558.x, 22226086.
18. Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013, 98:E867-E871. 10.1210/jc.2012-4205, 3706739, 23585665.
19. Sinclair A, Morley JE, Rodriguez-Manas L, Paolisso G, Bayer T, Zeyfang A, Bourdel-Marchasson I, Vischer U, Woo J, Chapman I, Dunning T, Meneilly G, Rodriguez-Saldana J, Gutierrez Robledo LM, Cukierman-Yaffe T, Gadsby R, Schernthaner G, Lorig K. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012, 13:497-502. 10.1016/j.jamda.2012.04.012, 22748719.
20. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011, 13:669-672. 10.1111/j.1463-1326.2011.01406.x, 21457428.
21. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 2012, 7:e30555. 10.1371/journal.pone.0030555, 3280264, 22355316.
22. Polidori D, Sakai M, Devineni D. Exposure-response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) [abstract]. Diabetes 2011, 60(suppl 1):A294.
23. Rosenstock J, Davies M, Dumas R, Desai M, Alba M, Capuano G, Meininger G. Effects of canagliflozin added on to basal insulin +/- other antihyperglycemic agents in type 2 diabetes [abstract]. Diabetes 2013, 62(suppl 1):A280.
24. Summary of Product Characteristics Forxiga 5 mg and 10 mg film-coated tablets 2012, Middlesex, United Kingdom: Bristol-Myers Squibb/AstraZeneca EEIG, Summary of Product Characteristics.
25. Hach T, Gerich JE, Salsali A, Kim G, Hantal S, Woerle HJ, Broedl UC. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials [abstract]. Diabetes 2013, 62(suppl 1):LB19.